Main menu
Edison Group
  • Home
  • Equities

    Equities

    View All Equities

    Equities by Sector

    Pharnext

    MCap

    1m

    Last close

    EUR0.10

    ▲ 0.03 (42.86%)

    SenSen Networks

    MCap

    AUD24m

    Last close

    AUD0.03

    ▲ 0.01 (36.36%)

    Lepidico

    MCap

    AUD39m

    Last close

    AUD0.00

    ▲ 0.00 (33.33%)

  • Sectors

    Sectors

  • Investment Strategy

    Investment Strategy

    View All

    Latest

  • Thematics

    Thematics

    View All Thematics

    Latest

  • Audiovisual

    Audiovisual

    View All Audiovisual

    Latest

Molecure – executive interview with Dr Samson Fung, Chief Medical Officer

Molecure – executive interview with Dr Samson Fung, Chief Medical Officer

Molecure — 2 videos in collection

More on this equity

Molecure is a clinical-stage biotechnology company. It uses its medicinal chemistry and biology capabilities to discover and develop first-in-class small molecule drug candidates that directly modulate underexplored protein targets and the function of RNA designed to treat multiple incurable diseases. Molecure has two lead assets in clinical trials: OATD-01 (a chitotriosidase inhibitor) in a Phase II study for the treatment of sarcoidosis, and OATD-02 (an ARG1/2 inhibitor) in a Phase I study for patients with advanced and/or metastatic solid tumours. 

In this video, Samson Fung, Molecure’s Chief Medical Officer, provides background on the clinical investigation of the company’s developmental pipeline.

< Previous
Next >

You may also be interested in these:

Healthcare

Molecure – executive interview with Marcin Szumowski, CEO

Subscribe to Edison

Get access to the very latest content matched to your personal investment style.

Sign up for free